Welcome to our dedicated page for Beta Bionics SEC filings (Ticker: BBNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Beta Bionics, Inc. (Nasdaq: BBNX) provides access to the company’s official U.S. Securities and Exchange Commission disclosures. As a commercial-stage medical device company focused on the iLet Bionic Pancreas for insulin-requiring people with diabetes, Beta Bionics uses its filings to report financial results, operational metrics, and significant corporate events.
Investors can review current reports on Form 8-K, which the company uses to announce quarterly financial results and other material information. Recent 8-K filings reference press releases detailing net sales, gross margin, operating expenses, net loss, cash and investment balances, and non-GAAP measures such as adjusted EBITDA, along with reconciliations to the most directly comparable GAAP measures.
Filings also describe operational indicators that are central to Beta Bionics’ business, including installed customer base, new patient starts, and the mix of reimbursement between the Durable Medical Equipment channel and the Pharmacy Benefit Plan channel. These disclosures help readers understand how the iLet Bionic Pancreas is being adopted and reimbursed in practice.
In addition, the company has filed 8-Ks to furnish investor and analyst presentations and to summarize “real-world” iLet data. These materials discuss changes from baseline HbA1c to glucose management indicator, hypoglycemia metrics, and outcomes for users transitioning from multiple daily injections or competitive hybrid-closed loop systems, as well as analyses of usage patterns such as “fully-closed loop” operation.
Through its registration of common stock on the Nasdaq Global Market under the symbol BBNX, Beta Bionics is subject to ongoing reporting obligations. On this page, AI-powered tools can assist by summarizing lengthy filings, highlighting key figures and definitions, and helping readers navigate topics such as non-GAAP metrics, risk factor discussions, and descriptions of clinical and real-world data included in exhibits.
For anyone researching BBNX, the SEC filings page is a primary source for understanding the company’s reported financial condition, regulatory communications, and the detailed context behind its press releases and investor materials.
Beta Bionics, Inc. Chief Commercial Officer Mark Hopman sold 353 shares of common stock in an open-market transaction on March 4, 2026. The shares were sold at an average price of $11.57 per share under a pre-arranged Rule 10b5-1 trading plan adopted on May 13, 2025.
After this sale, Hopman directly owned 139,133 shares of Beta Bionics common stock. The filing characterizes the transaction as an open-market sale, and the trading plan structure indicates it was executed under a pre-established schedule rather than at the insider’s discretion on the trade date.
BBNX submitted a Rule 144 notice listing a proposed sale of 353 common shares issued as an equity award, with a transaction date shown as 03/01/2026 and cash as the consideration. The filing also reports prior sales of 2,061 common shares by Mark Hopman on 12/04/2025 for $63,192.28.
Michael Mensinger reported proposed sales of Common Stock on Form 144 relating to equity received for services to the issuer. The filing lists securities vested as Restricted Stock Units on 03/01/2026 and shows multiple sales in the past three months.
The filing records sales of 1,063 shares on 12/02/2025, 7,200 shares on 01/02/2026, 600 shares on 01/02/2026, and 2,200 shares on 01/06/2026, with amounts shown alongside each entry.
Stephen Feider submitted a Form 144 notice reporting proposed sales of Common Stock tied to Beta Bionics, Inc./BBNX. The filing lists Restricted Stock Units vesting under a registered plan dated 03/01/2026 and shows prior sale entries dated 12/02/2025 and 01/02/2026.
Sean Saint reported a Form 144 sale notice relating to Common Stock of Beta Bionics, Inc. The filing lists 3,384 shares associated with restricted stock units vesting under a registered plan on 03/01/2026, with Morgan Stanley Smith Barney LLC named as broker on 03/02/2026.
The filing also shows prior sales of 3,278 shares on 12/02/2025 for $96,163.08. The securities are described as compensation for services rendered to the issuer.
Beta Bionics, Inc. Chief Commercial Officer Mark Hopman reported new equity awards and a small share sale. He received a grant of 109,105 shares of common stock as a restricted stock unit award under the company’s 2025 Equity Incentive Plan and 58,749 stock options, which vest in 36 equal monthly installments starting on March 1, 2026.
On March 2, 2026, he sold 834 shares of common stock in an open-market transaction at a weighted average price of $12.3616, in a price range between $12.20 and $12.55, to cover tax withholding obligations tied to restricted stock unit vesting. After this sale, he directly owned 139,486 shares of common stock.
Beta Bionics, Inc. Chief Medical Officer Russell Steven Jon reported multiple equity transactions. He sold 1,026 shares of common stock in an open-market transaction at a weighted average price of $12.3616 per share, with prices ranging from $12.20 to $12.55, to cover tax withholding obligations from vesting restricted stock units.
He also acquired 109,105 shares of common stock as a grant classified as a restricted stock unit award under the company’s 2025 Equity Incentive Plan. In addition, he received an employee stock option covering 58,749 shares, which is scheduled to vest in 36 equal monthly installments starting from March 1, 2026.
Beta Bionics, Inc. Chief Product Officer Mike Mensinger reported a mix of equity grants and a small share sale. On February 27, 2026, he received a grant of 58,749 employee stock options and 109,105 shares of common stock at a price of $0.0000 per share, including a restricted stock unit award under the company’s 2025 Equity Incentive Plan. The option award will vest in 36 equal monthly installments starting March 1, 2026. On March 2, 2026, he sold 1,064 shares of common stock in an open-market transaction at a weighted average price of $12.3616 per share to cover tax withholding obligations associated with restricted stock unit vesting, leaving him with 188,793 common shares directly held after that sale.
Beta Bionics, Inc. Chief Financial Officer Stephen Feider reported both stock awards and a small share sale. On February 27, 2026, he received 131,543 shares of common stock as restricted stock units and an option for 70,831 shares that vests in 36 equal monthly installments starting March 1, 2026. On March 2, 2026, he sold 1,428 shares of common stock at a weighted average price of $12.3616 to cover tax withholding obligations related to restricted stock unit vesting, and held 172,729 common shares directly afterward.
Beta Bionics, Inc. President & CEO Sean Saint reported a mix of equity awards and a small tax-related share sale. On February 27, 2026, he acquired 343,269 shares of common stock as a restricted stock unit award under the 2025 Equity Incentive Plan and received an employee stock option for 184,837 shares, which vests in 36 equal monthly installments starting March 1, 2026. On March 2, 2026, he sold 3,384 shares of common stock in an open-market transaction at a weighted average price of $12.3616, solely to cover tax withholding obligations from restricted stock unit vesting, and held 437,809 common shares directly afterward.